PBAC's latest decision on Tepotinib: Recommended with restriction (2021). Considered for Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations (METex14sk).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2021
Submissions
1
2021 → 2021
Eligible population
Adults 18 years or older with histologically and cytologically confirmed Stage IIIB (locally advanced) or Stage IV (metastatic) NSCLC with MET exon 14 skipping alterations, who are either treatment naïve or pre-treated with no more than 2 lines of prior therapy, with WHO performance status of 2 or less.
Therapy area
Oncology
Line of therapy
Any
Evidence base
Single-arm
Primary endpoint
ORR
Key trials
VISION
Comparator
pembrolizumab with chemotherapy
Economic model
Cost-minimisation
ICER note
Cost minimisation analysis; tepotinib proposed at effective price of pembrolizumab, no ICER calculated